Vericel (VCEL) Trading Up 5.1%

Shares of Vericel Corp (NASDAQ:VCEL) were up 5.1% during trading on Friday . The stock traded as high as $5.35 and last traded at $5.15. Approximately 663,716 shares changed hands during trading, an increase of 32% from the average daily volume of 501,065 shares. The stock had previously closed at $4.90.

Several analysts have commented on VCEL shares. BTIG Research reissued a “buy” rating and set a $6.00 price target on shares of Vericel in a research report on Thursday, September 7th. ValuEngine lowered shares of Vericel from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

The stock has a market cap of $178.03, a PE ratio of -5.85 and a beta of 3.03. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The business had revenue of $14.26 million during the quarter. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. equities research analysts predict that Vericel Corp will post -0.6 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in VCEL. Bank of New York Mellon Corp increased its holdings in shares of Vericel by 13.8% during the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 4,523 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Vericel during the third quarter valued at about $235,000. JPMorgan Chase & Co. acquired a new position in shares of Vericel during the third quarter valued at about $328,000. EAM Investors LLC acquired a new position in shares of Vericel during the third quarter valued at about $943,000. Finally, Perkins Capital Management Inc. increased its holdings in shares of Vericel by 118.4% during the third quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after acquiring an additional 305,000 shares in the last quarter. 33.12% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Vericel (VCEL) Trading Up 5.1%” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/12/22/vericel-vcel-trading-up-5-1.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

What are top analysts saying about Vericel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vericel and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit